UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Cancer immunotherapy is a type of cancer treatment that harnesses the immune system to fight cancer cells. The treatment ...
T cells are central mediators of autoimmune disease pathogenesis, yet their functional states are not defined solely by antigen recognition or canonical ...
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...
MB-105, a CD5-targeted CAR-T cell therapy, has received FDA regenerative medicine advanced therapy designation for relapsed/refractory CD5-positive T-cell lymphoma. The designation aims to expedite ...
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...
In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...
CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results